Abstract:Sialic acid-binding immunoglobulin-like lectins, also known as Siglecs, have recently been designated as glyco-immune checkpoints. Through their interactions with sialylated glycan ligands overexpressed on tumor cells, inhibitory Siglecs on innate and adaptive immune cells modulate signaling cascades to restrain anti-tumor immune responses. However, the elucidation of the mechanisms underlying these processes is just beginning. We find that when human natural killer (NK) cells attack tumor cells, glycan remodeling occurs on the target cells at the immunological synapse. This remodeling occurs through both the transfer of sialylated glycans from NK cells to target tumor cells and the accumulation of de novo synthesized sialosides on the tumor cells. The functionalization of NK cells with a high-affinity ligand of Siglec-7 leads to multifaceted consequences in modulating a Siglec-7-regulated NK-activation. At high levels of ligand, an enzymatically added Siglec-7 ligand suppresses NK cytotoxicity through the recruitment of Siglec-7 to an immune synapse, whereas at low levels of ligand an enzymatically added Siglec-7 ligand triggers the release of Siglec-7 from the cell surface into the culture medium, preventing a Siglec-7-mediated inhibition of NK cytotoxicity. These results suggest that a glycan engineering of NK cells may provide a means to boost NK effector functions for related applications.With the formation of an immune synapse during an NK-based killing, a cancer cell upregulates its cell-surface sialylation level primarily via an accumulation of neosialylation, and its mediated immune inhibition can be blocked with a cis high-affinity ligand created chemoenzymatically, which resulted in a better tumor growth control.This article has not yet been cited by other publications.

A new target for tumor innate immunity：sialic acid-binding immunoglobulin-like lectin (Siglec)-7/9

The intriguing roles of Siglec family members in the tumor microenvironment

Targeting the CD47-SIRPα Signaling Axis: Current Studies on B-cell Lymphoma Immunotherapy

The Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy

Sialic acid and Siglec receptors in tumor immunity and immunotherapy

Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy

Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy

Tumor Immune Checkpoints and Their Associated Inhibitors

Sialylated IgG in epithelial cancers inhibits antitumor function of T cells via Siglec-7.

Targeting Innate Sensing in the Tumor Microenvironment to Improve Immunotherapy

Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy

Targeting the Siglec–Sialic Acid Immune Axis in Cancer: Current and Future Approaches

Siglec-15 as an Emerging Target for Next-generation Cancer Immunotherapy

Modulation of Siglec-7 Signaling Via In Situ-Created High-Affinity cis -Ligands

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

Sialic Acids on Tumor Cells Modulate IgA Therapy by Neutrophils via Inhibitory Receptors Siglec-7 and Siglec-9

Innate immune cells in tumor microenvironment: A new frontier in cancer immunotherapy

Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy

Targeting Siglec–Sialylated MUC1 Immune Axis in Cancer

Cancer-derived sialylated IgG promotes tumor immune escape by binding to Siglecs on effector T cells

Aptamer-Assisted Blockade of the Immune Suppressor Sialic Acid-Binding Immunoglobulin-Like Lectin-15 for Cancer Immunotherapy